Advanced Hodgkin's Lymphoma Clinical Trial
1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD
regimens for patients with advanced Hodgkin's lymphoma.
2. To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma
This is a confirmatory open-label, randomized, controlled, multicenter study. Recruited
subjects are to be randomized to treatment group and controlled group, with ratio of 1:1.
Treatment group will accept baseline BEACOPP regimen, while controlled group will accept ABVD
regimen.
The study design consisted of a screening phase of 1 week, a treatment phase of 24 or 32
weeks, and a post treatment follow-up of at least 2 years.
;